ArticleAnnals of surgical oncology2026
Impact of Tumor Size on Neoadjuvant Chemotherapy Outcomes in Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemotherapy (NAC) is increasingly used in early breast cancer (BC) to assess chemosensitivity and guide postneoadjuvant treatment strategies. Although small tumors < 2 cm are often treated with upfront surgery because of their operability and presumed favorable prognosis, it remains uncertain whether patients with small tumors who do not achieve pathological complete response (pCR) might miss the opportunity for effective postneoadjuvant escalation strategies. We aimed to evaluate whether initial tumor size predicts pCR and residual disease burden across molecular subtypes.
methodsWe conducted a retrospective analysis of 714 patients with stage T1-T3N0-3M0 BC treated with NAC at Institut Curie between 2002 and 2012. Pathological response was assessed by using the Residual Cancer Burden (RCB) index (continuous and categorical). Pathological complete response was defined as ypT0/is ypN0. Associations between tumor size and response were evaluated by using univariate analyses, stratified by molecular subtype.
resultsThe overall pCR rate was 28%, reaching 38% in triple-negative BC (TNBC) and 39% in HER2-positive tumors, but only 5% in estrogen receptor/HER2-negative (luminal) tumors. Initial tumor size was linearly associated with continuous RCB score (p < 0.001); larger tumors showed greater residual disease. Tumor size was not associated with the likelihood of achieving pCR in any molecular subtype. Among tumors ≤ 2 cm, most had residual disease: 87% of luminal tumors, 46% of TNBC, and 34% of HER2-positive tumors were classified as RCB-II/III. Tumor size remained non-predictive of pCR in multivariate analysis (p = 0.8).
conclusionsInitial tumor size is not predictive of pCR after NAC. Small tumors, including those ≤ 2 cm, do not demonstrate higher pCR rates. Tumor size alone should therefore not be used to exclude patients-particularly those with TNBC or HER2-positive disease-from neoadjuvant treatment strategies that enable post-neoadjuvant therapeutic adaptation.
Indexed as
Identifiers
42627610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.